Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities

Tumor-specific T-cells could eliminate tumor cells with minimal long-term toxicity, but significant success in treating solid tumors remains limited.

• Current T-cell therapies have shown notable success in leukemia and lymphoma but struggle with solid tumors.
• Limited costimulatory and cytokine signaling in solid tumors may contribute to the challenges faced by T-cell therapies.
• Engineering CAR-T therapies to enhance cytokine signaling is likely necessary for improving responses against solid tumors.
• Concerns exist regarding the potential for unchecked proliferation and potency of engineered T-cells, highlighting the need for careful regulation.
• Methods to safely deactivate these engineered cells at the tumor site are essential for ensuring patient safety.

AI simplified